Desvenlafaxine Tablet, Extended Release
Product Images NDC 68788-8760

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 68788-8760). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Desvenlafaxine Extended-release Tablets 50mg (Desvenlafaxine Tablets 50mg 30s Label)

Desvenlafaxine Extended-Release Tablets 50 mg label by Preferred Pharmaceuticals Inc. The label includes the generic name, dosage form, and strength. It states each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. Manufacturer is Rubicon Research Private Limited. The label has spaces for package size, expiration date, lot and batch numbers, and instructions. It also features a barcode, drug transfer caution, and dosing directions in English and Spanish on a yellow background.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 1)

A chart presenting geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of desvenlafaxine extended-release tablets under conditions of renal and hepatic impairment, and in demographic subpopulations (gender and age). The x-axis shows change relative to reference values, comparing mild, moderate, and severe impairment and describing population categories such as females and elderly age groups.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 2)

A horizontal bar chart showing the geometric mean ratio and 90% confidence interval for pharmacokinetic changes due to CYP3A4 inhibitors (Ketoconazole) on Cmax and AUC. The chart plots values relative to reference on a scale from 0.5 to 2.0, with Cmax near 1.08 and AUC near 1.43.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 3)

A forest plot chart illustrating the geometric mean ratio (90% confidence intervals) of pharmacokinetic parameters (Cmax, AUC, AUCinf) for various drugs interacting with Desvenlafaxine. Interacting drugs include Desipramine, Midazolam, Tamoxifen, and Aripiprazole at different doses, showing relative changes compared to reference values.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 4)

A Kaplan-Meier curve showing estimated proportion of patients with relapse (%) over time in days from randomization, comparing Desvenlafaxine 50 mg (solid blue line) versus Placebo (dashed red line). The graph illustrates relapse rates over approximately 200 days.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Figure 5)

A Kaplan-Meier survival curve showing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph compares two groups, one treated with desvenlafaxine (solid blue line) and the other with placebo (dashed red line), illustrating lower relapse rates in the desvenlafaxine group over approximately 180 days.*

FDA Label Image

Image Description (Desvenlafaxine Tablets Structure)

Chemical structure diagram of desvenlafaxine monohydrate, showing its molecular components and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.